Satellos Bioscience
MSLE
Satellos Bioscience (MSLE) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Aug 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $11.00 | Jul 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 | May 18, 2026 |
| Guggenheim | Initiated Coverage | Buy | $23.00 | Apr 28, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $20.00 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 from $1.20 | Mar 30, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 11, 2026 |
Frequently asked questions
What is the latest analyst rating on MSLE?
On Aug 17, 2026, HC Wainwright & Co. maintained Satellos Bioscience at Buy with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.